Findings from the phase 3 PANOVA-3 trial showed that adding tumor treating fields to gemcitabine and nab-paclitaxel prolonged time to quality-of-life deterioration and improved pain outcomes in unresectable, locally advanced pancreatic cancer.
The FDA accepted a BLA with priority review for sonesitatug vedotin in previously treated CLDN18.2-positive gastric/GEJ cancer based on OS data from CLARITY-Gastric01.
The designation supports development of onvansertib plus FOLFIRI/bevacizumab as first-line therapy for KRAS- or NRAS-mutated metastatic colorectal cancer, based on phase 2 CRDF-004 findings.
Mark A. Lewis, MD, explains when unexpected disease behavior in neuroendocrine tumors should prompt a specialist referral and how patients can still be treated close to home.